乙型肝炎病毒表面抗原S基因在人5型重组腺病毒中的表达及其特性

The hepatitis B virus (HBV) S gene, PreS2 + S genes and the late phase expression cassette (MTI) + HBV S genes were separately cloned into Ad5 vector downstream of E3 promoter (pAd5 deltaE3 provided by Wyeth Co.). The above constructed plasmids and Ad5 DNA EcoR I A fragment were cotransfected into 293 cells. The progeny adenoviruses named rAd5S, rAd5MS, rAd5S2S were harvested for analysis. The recombinants were isolated and analyzed by PCR, using two primers specific to the HBV S genes. The expressed products were detected by ELISA and RIA. The recombinant containing MIT + HBV S genes (rAd5MS) was identified to be ELISA positive, whereas the other two recombinants (rAd5S, rAd5S2S) were negative to ELISA, but positive to RIA. The results indicated that adenovirus E3 early promoter could express the inserted foreign genes, and MIT worked well in the E3 region of Ad5 and could increase the expression capacity of the recombinants. The conditions for foreign gene expression and genetic stability of the recombinant viruses were studied in detail. There was no wild Ad5 discovered during the cotransfection experiments. The present study provides some experiences for studying adenovirus recombination.     

4型腺病毒疫苗株载体的构建及β—半乳糖苷酶基因的 …

目的 构建缺失Ｅ３区７８．９－８６ｍｕ的４型腺病毒疫苗株载体。方法 从４型腺病毒疫苗株感染的人胚肺二倍体细胞２ＢＳ中提取病毒ＤＮＡ,经过多卡亚克隆构建成功缺失７８．９￣８６ｍｕ的载体。将含有ＣＭＶ早期启动子的β－半乳糖苷酶基因插入缺失部位,将这一重组质粒与Ａｄ４Ｂｃｌ１大片段共转染２９３细胞,铺含有Ｘ－Ｇａｌ的营养琼脂,经蓝色斑斑纯化三代,ＯＮＰＧ法测定β－半乳糖苷酶基因的表达量。结果 所构建的载     

Matching complementing functions of transformed cells with stable expression of selected viral genes for production of E1-deleted adenovirus vectors

Production of E1-deleted adenovirus (rAd) vectors requires complementation by E1A and E1B functions provided by the production cell line. The two cell lines most commonly used for production of rAd vectors, 293 and Per.C6, were derived from human primary cells and contain contiguous E1A and E1B sequences from the Ad genome. As an alternative system, we tested complementation of rAd vectors using sequential transfection of individual E1A and E1B expression cassettes into A549 human lung tumor cells, which support highly efficient replication of wild type adenovirus. We found that E1A function could be complemented in A549 cells by the mutant E1Adl01/07, and that E1B function could be provided in such cells using only the 55K E1B gene. Production yields in the resulting producer cell line, designated SL0003, were similar to those obtained from 293 cells without generation of detectable recombinant replication competent adenovirus.     

柯萨奇病毒B3VP1重组腺病毒载体疫苗rAd/VP22-L-VP1的构建及表达**

背景：VP22是单纯疱疹病毒1型(Herpes simplex virus type 1,HSV-1)UL49基因编码的碱性蛋白质,具有蛋白转导结构域(protein transduction domain, PTD),能够把与之融合的蛋白或与之结合的DNA 等大分子跨膜送递到邻近细胞,在基因靶向预防中表现出优势。 目的：构建表达单纯疱疹病毒1型VP22与柯萨奇病毒B3主要中和抗原VP1融合蛋白的重组腺病毒载体疫苗,观察外源基因在HEK293细胞中的良好表达。 方法：PCR法扩增目的基因HSV-1 VP22和CVB3 VP1,经Linker连接,将VP22-L-VP1插入腺病毒穿梭载体pAdTrack-CMV,构建重组穿梭质粒AdTrack-CMV/VP22-L-VP1。再将此载体与腺病毒骨架载体pAdEasy-1在大肠杆菌BJ5183中进行同源重组,生成重组腺病毒质粒pAd/VP22-L-VP1,脂质体介导pAd/VP22-L-VP1转染HEK293细胞包装重组腺病毒rAd/VP22-L-VP1。HEK293细胞上进行病毒扩增和滴定并检测外源基因的表达。 结果与结论：构建的重组腺病毒载体pAd/VP22-L-VP1经过第4轮扩增,其滴度达到6.77×107 pfu/mL,体外感染293细胞可见VP22和VP1融合蛋白的表达。说明实验成功构建并包装重组腺病毒rAd/VP22-L-VP1。     

Recombinant adenovirus co-expressing capsid proteins of two serotypes of foot-and-mouth disease virus (FMDV): in vitro characterization and induction of neutralizing antibodies against FMDV in swine

Human adenovirus type 5 (Ad5) has been evaluated as a novel gene delivery vector for the development of live-viral vaccines for foot-and-mouth disease (FMD). In this study, we constructed an Ad5 vector co-expressing the capsid precursor proteins, P1, of FMD virus (FMDV) field strains A24 Cruzeiro and O1 Campos and examined the neutralizing antibody responses in swine after inoculation with the vector. To construct the Ad5 vector, a bicistronic expression cassette containing a cytomegalovirus promoter, the P1 coding sequence of FMDV A24, the internal ribosomal entry site (IRES) of FMDV A12, the P1 coding sequence of FMDV O1 Campos and the coding region of A12 3C protease was inserted into the E1 region of an E1/E3-deleted Ad5. The recombinant adenovirus, Ad5A24+O1, was generated by transfection of 293 cells with full-length pAd5A24+O1 recombinant plasmid DNA. The recombinant Ad5 co-expressed P1 of both A24 and O1 in infected 293 cells and P1 of both serotypes was processed to produce VP0, VP3, and VP1. We further demonstrated the formation of capsid protein complexes by co-precipitation of VP0, VP3, and VP1 with monoclonal antibodies against viral capsid proteins. Swine inoculated with Ad5A24+O1 generated neutralizing antibodies against both A24 and O1. However, the overall neutralizing antibody response was considerably lower than that induced by a commercial FMD vaccine or a monovalent Ad5-A24 vaccine.     

Immunogenicity of the recombinant adenovirus type 5 vector with type 35 fiber containing HIV-1 gag gene

The immune efficiency of a recombinant adenovirus type 5 with type 35 fiber containing HIV-1 gag gene (rAd5/F35-mod.gag) was investigated in BALB/c mice, in which the rAd5/F35-mod.gag was firstly identified with PCR, then transfected to 293 cells and the in vitro expression level of Gag protein was determined by Western blotting and indirect immuno-fluorescent assay. Mice were immunized with intramuscular injections of rAd5/F35-mod.gag, rAd5-mod.gag or DNA and were boosted after 3 weeks. To test the effect of pre-existing anti-viral immunity on immunization, mice were also injected with Ad5-GFP vector and then immunized 4 and 7 weeks later with Ad5/F35-mod. gag vector. The P24-specific IgG antibody in sera of immunized mice was determined by ELISA and the specific cytotoxic T lymphocyte (CTL) response was assayed by intracellular cytokine staining. It was demonstrated that the rAd5/F35-mod. gag vector could express efficiently the HIV Gag protein in 293 cells in vitro and induce strong HIV-specific immune responses in vivo. The strongest CTL and serum IgG response occurred when mice were immunized twice with injection of rAd5/F35 alone, but the anti-Ad5 antibody after primary infection with adenovirus could inhibit the specific immune responses induced by rAd5/F35 vector. It is concluded that single immunization with recombinant adenovirus rAd5/F35-mod. gag can induce specific CTL and serum IgG antibody responses in mice, but the immunogenicity of rAd5/F35 is comparably weaker than that of rAd5.     

7型腺病毒疫苗株载体的构建及β—半乳糖苷酶基因 …

目的 构建Ｅ３区缺失的７型腺病毒疫苗株（Ａｄ７ｖ）载体并表达β－半乳糖苷酶基因。方法 从人二倍体细胞的Ｗ１３８培养的Ａｄ７ｖ中分离病毒ＤＮＡ，利用Ａｄ７ｖＤＮＡ天然的酶切位点，经过多步亚克隆，克隆的同时将Ｅ３区７８．８－８７ｍｕ片段缺失，并将多克隆酶切位点带入Ａｄ７ｖ载体。为了验证载体的功能，将带有巨细胞病毒（ＣＭＶ）早期启动子β－半乳糖苷酶基因插入缺失的Ｅ３区。将这一重组质粒和ＥｃｏＲＩ酶切Ａｄ     

Nucleic acid hybridization for detection of cell culture-amplified adenovirus.

A number of recombinant plasmids containing genomic segments of adenovirus were constructed. Seven cloned probes, as well as total adenovirus type 2 (Ad2) and Ad16 genomic DNA, were tested by a nucleic acid hybridization technique for sensitivity and specificity in detecting adenoviruses in infected cells. Adenovirus DNA was spotted onto a nitrocellulose filter and hybridized with 32P-labeled DNA probes. The probes, total Ad2 genomic DNA, and plasmid pAd2-H (containing the hexon gene from Ad2 DNA) all detected 10 reference serotypes of five genomic subgroups (A through E) with similar sensitivities. However, plasmid pAd2-H required less preparation time than did total Ad2 DNA. Probes pAd2-F (containing the fiber gene from Ad2) and pAd16-BD (containing the BamHI D fragment from Ad16) hybridized only with reference serotypes from the homologous subgroups (C and B, respectively). Of 101 patient isolates amplified in cells, pAd2-H detected 100% of all isolates from both the homologous and the heterologous subgroups. The detection rates for pAd2-F were 100% (subgroup C) and 3.6% (subgroups A, B, and D), and those for pAd16-BD were 100% (subgroup B) and 9.4% (subgroups A, C, and D). A commercial biotinylated product (Pathogene II) was also included in this study for comparison.     

腺病毒细菌重组系统表达Crg-2蛋白的实验研究

目的利用腺病毒的细菌重组系统表达同时具有免疫趋化及血管抑制活性的趋化性细胞因子Crg-2重组蛋白。方法首先在大肠杆菌BJ5183中将穿梭质粒pShuttle-cmv/crg-2与AdE1区基因缺失的骨架质粒pAdEasy-1进行同源重组,筛选后脂质体法转染入具有AdE1区组成性表达的293包装细胞中进行病毒包装、扩增;Westernblot检测病毒感染293细胞的蛋白表达;趋化实验检测感染细胞上清对激活T淋巴细胞的趋化活性。结果穿梭质粒pShuttle-cmv/crg-2与骨架质粒pAdEasy-1重组后,经酶切及PCR鉴定获得重组腺病毒基因组质粒pAd/crg-2;病毒Ad/crg-2经包装并扩增后,用组织培养感染半数剂量法(TCID50)法测定病毒滴度达4×109TCID50/L,感染细胞经Westernblot检测有一接近Mr10000蛋白条带,分泌上清对激活的脾淋巴细胞有明显的趋化作用。结论采用细菌重组法成功获得重组腺病毒Ad/crg-2,可高效表达趋化性细胞因子Crg-2。     

人胸腺基质淋巴生成素基因重组腺病毒载体的构建及表达

目的: 构建含人胸腺基质淋巴生成素基因(TSLP)的重组腺病毒载体并表达, 以研究其免疫学功能。方法: 将由人胚肺细胞扩增得到的TSLP基因, 克隆于真核表达载体pcDNA3. 1中, 再亚克隆至穿梭质粒pShuttle中, 并与腺病毒骨架载体pAdEasy -1共同转化大肠杆菌。以获得的重组质粒线性化后转染HEK293细胞, 并包装成病毒颗粒。采用PCR法对重组腺病毒基因进行鉴定, 并以Westernblot检测TSLP蛋白的表达。结果: 通过细菌内同源重组, 成功构建带有人胸腺基质淋巴生成素基因的重组腺病毒质粒, 转染 293细胞后, 包装的重组病毒经PCR检测表明, 基因组含有目的基因,病毒的滴度可达 1×1011pfu/L。Westernblot证实, 感染的肿瘤细胞中有相应基因产物的表达。结论: 通过菌内重组可高效制备带有特定基因的重组病毒。所制备的Ad -TSLP可成功表达相应基因产物, 为进一步研究这一新型细胞因子的功能奠定了基础。     

靶向型辅助腺病毒的构建及其功能研究

目的构建一种新型辅助腺病毒,并用于靶向型第三代腺病毒载体的制备,提高其对造血细胞的感染效率。方法采用重叠PCR的方法合成含有不完全包装信号序列A1-A4和loxP序列的DNA片段SynES,替换穿梭质粒pShuttle中原有的包装信号序列,得到穿梭质粒pShuttle-SynES;将所得穿梭质粒与骨架质粒Ad5/F11p在大肠杆菌BJ5183中同源重组,获得重组腺病毒质粒载体pAd5/F11p-HV,将其转染293细胞包装重组腺病毒Ad5/F11p-HV。参照第三代腺病毒包装策略,利用Ad5/F11p-HV包装获得携带绿色荧光蛋白(GFP)基因的第三代腺病毒HD-Ad5/F11p-GFP;将其以不同的感染强度感染人白血病细胞系K562、U937、Jurkat和人脐带血CD34+细胞后,采用荧光显微镜和流式细胞术检测GFP的表达。结果采用DAN片段SynES替换穿梭质粒pShuttle上的包装信号,获得新的穿梭质粒pShuttle-SynES;进一步构建获得重组腺病毒质粒pAd5/F11p-HV,并制备了辅助腺病毒Ad5/F11p-HV。采用该辅助腺病毒包装pC4HSU-GFP,获得了第三代腺病毒HD-Ad5/F11p-GFP;CsCl密度梯度离心分离HD-Ad5/F11p-GFP和Ad5/F11p-HV,获得了高质量的HD-Ad5/F11p-GFP。与对照病毒HD-H14-GFP相比,HD-Ad5/F11p-GFP可明显提高对人白血病细胞U937、Jurkat和人脐带来源CD34+细胞的感染效率。结论设计并构建了一种靶向性辅助腺病毒,并以此为基础成功制备了对造血细胞高效感染的第三代重组腺病毒。     

登革Ⅰ型病毒E蛋白在293T细胞中的分泌表达

目的 分泌表达登革Ⅰ型病毒prM/E基因,为研究该蛋白的免疫学功能和特性奠定基础.方法 用RT-PCR法获得登革Ⅰ型病毒广州分离株全长prM/E基因,在prM基因前添加乙型脑炎病毒的信号肽或同时替换E基因羧基末端的20%为乙脑病毒E基因相应的部分,分别将其克隆入真核表达载体pcDNAS/FRT中,获得三种重组质粒DlprME-pc5,D1JsprME-pc5,D1JsprM80E20JE-pc5.用脂质体法分别将重组质粒DNA转入293T细胞,通过免疫荧光、Western印迹检测外源基因在真核细胞中的分泌表达.结果 用免疫荧光法检测到分别转染了三种重组质粒的293T细胞的胞质中均有登革Ⅰ型病毒蛋白的表达.Western印迹检测转染了D1prME-pc5重组质粒的293T细胞上清中没有特异蛋白条带,转染了经基因改造的重组质粒D1JsprME-pc5和D1JsprM80E20JE-pc5的细胞上清中均存在登革Ⅰ型病毒的特异蛋白条带.结论 转染了三种重组质粒的293T细胞均可表达登革Ⅰ型病毒prM/E蛋白,只有在prM基因前添加了信号肽的重组质粒转染后蛋白才获得分泌表达.     

Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice

Given the promise of recombinant adenovirus type 5 (rAd5) as a malaria vaccine carrier in preclinical models, we evaluated the potency of rAd35 coding for Plasmodium yoelii circumsporozoite protein (rAd35PyCS). We chose rAd35 since a survey with serum samples from African subjects demonstrated that human Ad35 has a much lower seroprevalence of 20% and a much lower geometric mean neutralizing antibody titer (GMT) of 48 compared to Ad5 (seroprevalence, 85%; GMT, 1,261) in countries with a high malaria incidence. We also demonstrated that immunization with rAd35PyCS induced a dose-dependent and potent, CS-specific CD8(+) cellular and humoral immune response and conferred significant inhibition (92 to 94%) of liver infection upon high-dose sporozoite challenge. Furthermore, we showed that in mice carrying neutralizing antibody activity against Ad5, mimicking a human situation, CS-specific T- and B-cell responses were significantly dampened after rAd5PyCS vaccination, resulting in loss of inhibition of liver infection upon sporozoite challenge. In contrast, rAd35 vaccine was as potent in naive mice as in Ad5-preimmunized mice. Finally, we showed that heterologous rAd35-rAd5 prime-boost regimens were more potent than rAd35-rAd35 because of induction of anti-Ad35 antibodies after rAd35 priming. The latter data provide a further rationale for developing rAd prime-boost regimens but indicate that priming and boosting Ad vectors must be immunologically distinct and also should be distinct from Ad5. Collectively, the data presented warrant further development of rAd35-based vaccines against human malaria.     

腺病毒介导的T-bet基因转染诱导Th1型淋巴细胞分化

目的：构建含有T细胞转录因子T-bet(T-box expressed in T cells)的重组腺病毒Ad.T-bet，并诱导Th1型淋巴细胞分化。 方法： 采用RT-PCR的方法从健康人外周血淋巴细胞的总RNA中克隆T-bet基因，亚克隆入腺病毒穿梭载体成为pAdtrack-CMV.T-bet，与腺病毒基因组载体pAdeasy-1同源重组为pAd.T-bet，经Pac I酶切后转染293细胞，用 Western blotting 和RT-PCR的方法鉴定Ad.T-bet；联合腺病毒和脂质体以感染倍数(m.o.i) 5000感染活化的淋巴细胞，用ELISA 法检测培养液中IFN-γ含量。 结果： 采用RT-PCR方法从健康人外周血淋巴细胞中扩增出T-bet基因，构建出重组腺病毒Ad.T-bet，Western blotting 和RT-PCR均检测出细胞内T-bet蛋白表达；联合Ad.T-bet和脂质体感染淋巴细胞诱导Th1型细胞因子IFN-γ持续高表达。 结论： 重组腺病毒Ad.T-bet有效诱导Th1型细胞分化，有望成为改变肿瘤患者免疫抑制状态的有效方法。     

人LIGHT基因的克隆及其重组腺病毒载体的构建

目的 克隆人LIGHT基因，构建其重组腺病毒载体，以研究LIGHT过表达与腺病毒感染对细胞生长的影响。方法 用RT-PCR法从人外周血单个核细胞（PBMC）中克隆人的LIGHT全长基因。将LIGHT cDNA克隆到穿棱载体pAdTrack-CMV-LIGHT重组质粒中，经酶切线性化后，将重组质粒pAdTrack-CMV-LIGHT和骨架质粒pAdEasy-1，以电穿孔法共转染大肠杆菌BJ5183，获得重组腺病毒质粒。最后，将线性化的重组腺病毒质粒转染293细胞包装获得重组腺病毒，用荧光显微镜、PCR及Western blot分析LIGHT基因的表达。结果 用RT－PCR法从人的PBMC中，扩增出723bp的cDNA，测序证实为人LIGHT基因。荧光显微镜、PCR及Western blot证实，LIGHT重组腺病毒可感染293细胞，并在293细胞内进行有效的复制。结论 成功地克隆了人LIGHT基因，并构建了其重组腺病毒载体，为进一步研究LIGHT基因的功能提供了条件。     

表达人B7-1的重组腺病毒的制备及初步鉴定

目的构建表达B7-1基因的重组腺病毒载体,制备相应的复制缺陷型重组腺病毒并检测其在喉癌细胞中的表达。方法构建携带人B7-1基因的重组穿梭载体pAdtrack-B7-1,PmeI线性化后与腺病毒载体pAdEasy-1共转化大肠杆菌BJ5183,通过同源重组得到重组腺病毒载体pAd-B7-1。将重组腺病毒载体转染HEK293包装细胞制备重组腺病毒,应用病毒悬液感染人喉癌细胞株,RT-PCR检测感染细胞中B7-1基因mRNA表达。结果酶切鉴定证实阳性pAdTrackB7-1重组穿梭载体含有目的基因B7-1,同源重组后制备的病毒载体DNA经酶切鉴定获得了阳性重组腺病毒载体,该载体能有效转染HEK293细胞并在细胞内成功包装,转染3d后可以观察到绿色荧光蛋白(GFP)表达并逐渐增多、增强。制备的Ad-B7在体外能有效感染Hep-2细胞,感染后可维持6d高水平的B7-1的表达,整体表达可持续两周。结论成功构建了同时表达B7-1的重组腺病毒载体并制备出重组腺病毒颗粒,该病毒能有效地感染喉癌细胞并表达高水平的B7-1基因,为进一步研究B7-1的功能及应用B7-1进行基因治疗奠定基础。     

携带中国株HIV-1 gp120基因的重组腺病毒的构建及其感染巨噬细胞的形态学研究

目的: 构建携带中国株HIV-1 gp120基因并可感染小鼠骨髓来源巨噬细胞(BMM)的重组腺病毒。方法: 利用AdMax腺病毒构建系统,以双质粒共转染人胚肾转化细胞293Ad5⁺细胞,完成重组腺病毒载体包装,并进一步扩增和纯化。通过ELISA测定gp120的蛋白产量,以确认目的基因重组与表达成功。以Karber法对病毒进 行TCID₅₀滴度测定,利用BMM进行感染复数(MOI)流式细胞术测定,并利用荧光显微镜观察细胞活化形态。结果: 成功构建AdMax-HIV-1 gp120(简称Ad-gp120)及其对照病毒(Ad-GFP),其滴度分别为10^8.3和10^8.1 TCID₅₀/mL。这些病毒可感染BMM,MOI测定结果表明2种重组腺病毒感染BMM和293Ad5⁺细胞的能力接近,验证了上述TCID₅₀滴度结果。Ad-gp120可在293Ad5⁺细胞中表达gp120蛋白,并可感染和诱导BMM相关形态改变。结论: 成功构建Ad-gp120,其感染可致BMM出现形态发生改变。     

草原兔尾鼠卵透明带3基因重组腺病毒载体的构建及表达

目的:探索制备免疫不育疫苗的新途径,获得草原兔尾鼠卵透明带3(LZP3)重组腺病毒减毒活疫苗。方法:将LZP3基因亚克隆到穿梭质粒pShuttle-CMV上,采用细菌内同源重组"两步转化法"构建携带LZP3基因的重组腺病毒载体。获得的重组腺病毒载体线性化后转染HEK293细胞,包装成病毒颗粒。PCR鉴定重组腺病毒,继而用鉴定正确的重组腺病毒感染HeLa细胞,并以RT-PCR、Western blot检测LZP3的转录和表达。结果:成功构建了携带LZP3基因的重组腺病毒pAd-LZP3载体,其转染293细胞后包装出重组病毒,PCR证实LZP3基因已整合至腺病毒基因组中,病毒的滴度可达1.2×1010pfu/L。RT-PCR和Western blot检测表明RAd-LZP3感染的HeLa细胞中LZP3基因能够有效转录和表达。结论:制备的RAd-LZP3可成功表达LZP3基因,为后续开展RAd-LZP3免疫动物的研究奠定了基础。     

含HIV-1 gag基因的重组腺病毒5型与35型嵌合病毒免疫效果研究

目的探讨含HIV-1 gag基因的重组腺病毒5型与35型嵌合病毒(rAd5/F35)在BALB/c小鼠中的免疫效果。方法PCR,间接免疫荧光鉴定HIV-1gag基因在重组腺病毒(rAd5/F35-mod.gag)的正确插入和体外细胞水平的表达,用rAd5/F35-mod.gag以不同的方式免疫BALB/c小鼠,ELISA检测小鼠血清中的p24特异性抗体,细胞内细胞因子染色法检测小鼠的特异性细胞毒性T淋巴细胞(CTL)应答。结果重组腺病毒rAd5/F35-mod.gag在体外细胞水平可以很好的表达目的基因gag;在小鼠体内重组腺病毒rAd5/F35-mod.gag可诱导特异性的CTL应答和血清IgG抗体反应,用rAd5/F35单独免疫2次,所诱发的CTL和血清IgG反应最强。但Ad5初次感染后,产生的抗Ad5抗体可以抑制rAd5/F35疫苗的特异性免疫反应。结论重组腺病毒rAd5/F35-mod.gag单独免疫可在小鼠体内诱导特异性的CTL应答和血清IgG抗体反应。只改变Ad5纤突蛋白Fiber,不能避免抗Ad5抗体的抑制作用。